We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more OK
Menu Search : Home

You are here:

  • Home
  • About Roche
  • Therapy Areas
  • Safety, Health and Wellbeing
  • Media
  • Social Value
  • Careers
  • Contact Us
Statement on Ronapreve 18th Jan from Cipla

Statement on Ronapreve™

Ronapreve™ (Casirivimab 120mg/ml and Imdevimab 120mg/ml Injection for intravenous infusion or subcutaneous administration) does not retain activity against the Omicron variant.

Read More

Global Analytics and Technology Center of Excellence (GATE)

Global Analytics and Technology Center of Excellence (GATE)

 More
Supply Chain Business Continuity Amidst The Corona Virus Pandemic.

Supply Chain Business Continuity Amidst The Corona Virus Pandemic.

 More

Supporting patients in their journey - The Blue Tree programme

 More
Roche India certified as Great Place to Work

Roche India certified as Great Place to Work

 More

Making a difference – Social Value at Roche

More
Haemophilia

Haemophilia

 More
Cancer immunotherapy

Cancer immunotherapy

 More
Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close
  • © 2022
  • 21.04.2022
  • Legal Statement
  • Privacy Policy
  • Cookie Preferences.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, please call the Roche India Safety Unit on +91-98201 63752 or E-mail: [email protected]